TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by New York State Teachers Retirement System

New York State Teachers Retirement System raised its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,764 shares of the biopharmaceutical company’s stock after acquiring an additional 837 shares during the quarter. New York State Teachers Retirement System’s holdings in TG Therapeutics were worth $1,317,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Blue Trust Inc. increased its holdings in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares during the period. Synergy Asset Management LLC acquired a new stake in TG Therapeutics in the 4th quarter worth approximately $75,000. GAMMA Investing LLC increased its position in TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares during the period. KBC Group NV increased its position in shares of TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,092 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new stake in TG Therapeutics in the 3rd quarter valued at $111,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 0.2 %

NASDAQ TGTX opened at $30.88 on Monday. The business’s 50-day moving average is $31.07 and its 200 day moving average is $27.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market capitalization of $4.81 billion, a PE ratio of -308.77 and a beta of 2.26. TG Therapeutics, Inc. has a 1 year low of $12.90 and a 1 year high of $36.84.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. TD Cowen began coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. increased their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. The Goldman Sachs Group lifted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Wednesday, January 15th. Finally, StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 10.50% of the company’s stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.